Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00781859 · ClinicalTrials.gov registry record · Phase 3

Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.

A Phase 3 study, sponsored by ThromboGenics.

Completed
Registry status
Phase 3
Development phase
326
Enrollment target

NCT00781859: Completed Phase 3 study, sponsored by ThromboGenics.

NCT00781859 is a Phase 3 study that has completed, run by ThromboGenics. The registered enrollment target is 326 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00781859, a Phase 3 study, has completed, sponsored by ThromboGenics.

COMPLETED
Registry status
Phase 3
Development phase
326 participants
Enrollment target

Study Summary

The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.

Primary Outcome

The primary efficacy endpoint was the proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at Day 28 post-injection, as determined by masked Central Reading Center (CRC) Optical Coherence Tomography (OCT) evaluation. Any subjects who had a creation of an anatomical defect (i.e. retinal hole, retinal detachment) that resulted in loss of vision or that required additional intervention were not counted as successes for this primary endpoint.

Interventions

  • DRUG Placebo
  • DRUG 125 µg Ocriplasmin

Trial Details

FieldValue
Enrollment Target 326 participants
Start Date 2008-12
Est. Completion 2010-04
Phase Phase 3
ThromboGenics

12 total trials

What the finished NCT00781859 record still lists

NCT00781859 is an interventional study that assigns participants to a tested intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00781859 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00781859 about?

NCT00781859 is a clinical study titled "Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.". The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.

What is the current status of trial NCT00781859?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2008-12. Estimated completion is 2010-04.

What interventions are being tested in trial NCT00781859?

The interventions under investigation include: Placebo (DRUG), 125 µg Ocriplasmin (DRUG).

Who is sponsoring clinical trial NCT00781859?

This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00781859's enrollment target sits among peer trials

326 1075th of 2000 higher than 925 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06410144 · 326 participants · NA

    Chronic Kidney Disease-Education (CKD-EDU)

  • NCT06586619 · 326 participants · NA

    A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV

  • NCT07040566 · 326 participants · Phase 2

    A Trial of Varenicline for E-cigarette Cessation

  • NCT07165860 · 326 participants · NA

    Clinical Trial to Reduce Perinatal Intimate Partner Violence

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00781859, the US trial registry maintained by the National Library of Medicine. NCT00781859 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.